We followed the previous recommendation to consider diffuse cytoplasmic staining with moderate to intense staining in >80% of tumor cells as positive dysregulated expression; however, weak staining is negative, and heterogenous staining is equivocal [24]; however, using specific anti-BRAF monoclonal antibodies is recommended in future studies to uncover the mutational status of the tested samples. The gene discussed is BRAF; the disease is neoplasm.